TITLE

2008 - Intensive insulin therapy reduced long-term risk for incident hypertension in type 1 diabetes

AUTHOR(S)
Tsapas, Apostolos
PUB. DATE
February 2009
SOURCE
ACP Journal Club;2/17/2009, Vol. 150 Issue 2, p10
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article presents a research conducted by researcher I.H. de Boer and colleagues on how does intensive insulin therapy (IIT) compare with conventional therapy for development of hypertension in patients with type 1 diabetes. The study was conducted on 1441 patients of 13 to 39 years of age comprising two cohorts: primary prevention and secondary intervention.
ACCESSION #
36911246

 

Related Articles

  • Trends in hyperlipidemia and hypertension management in type 2 diabetes patients from 1998-2004: a longitudinal observational study. Greving, Jacoba P.; Denig, Petra; De Zeeuw, Dick; Bilo, Henk J. G.; Haaijer-Ruskamp, Flora M. // Cardiovascular Diabetology;2007, Vol. 6, p25 

    Background: Lack of treatment initiation or intensification might explain why some patients with type 2 diabetes do not reach target goals. The objective is to assess trends in risk factor treatment, and identify determinants for medication adjustments in patients with uncontrolled hypertension...

  • Peroxisome proliferator-activated receptor-γ agonist troglitazone protects against nondiabetic glomerulosclerosis in rats. Ma, Li-Jun; Marcantoni, Carmelita; Linton, Macrae F.; Fazio, Sergio; Fogo, Agnes B. // Kidney International;May2001, Vol. 59 Issue 5, p1899 

    Peroxisome proliferator-activated receptor-γ agonist troglitazone protects against nondiabetic glomerulosclerosis in rats.. Background.: Peroxisome proliferator-activated receptor-γ (PPARγ) is a member of the nuclear receptor superfamily of ligand-dependent transcriptional factors with...

  • Clinical: Commentary - Your weekly review of key GP guidance from MIMS. Gnanapragasam, Vasa // GP: General Practitioner;6/17/2005, p55 

    The article discusses diabetes. Not so long ago diabetes was considered to be a problem due to insulin deficiency. Prescribing sulphonyl urea or insulin was the key therapeutic intervention. Nowadays achieving glycaemic control is no longer seen as the beginning and end of care. A recent issue...

  • Initiating and Titrating Insulin in Patients With Type 2 Diabetes. Henske, Joseph A.; Griffith, Michelle L.; Fowler, Michael J. // Clinical Diabetes;Spring2009, Vol. 27 Issue 2, p72 

    The article presents a case study of a 48-year-old African-American man suffering from type 2 diabetes. His diabetes was complicated by peripheral neuropathy; and his medical history also included obesity, hyperlipidemia, and hypertension. He was taking sitagliptin, but the drug caused diarrhea....

  • Managing hypertension in patients with type 2 diabetes mellitus. Dobesh, Paul P. // American Journal of Health-System Pharmacy;6/15/2006, Vol. 63 Issue 12, p1140 

    Purpose. Current guideline recommendations for effective strategies to optimize the treatment of patients with concomitant hypertension and type 2 diabetes mellitus are reviewed. Summary. Current estimates indicate that 20 million people in the United States have diabetes, 90–95% of whom...

  • Intensive BP control in diabetes.  // Clinical Cardiology Alert;Aug2010 Supplement, p16 

    The article discusses research being done on intensive blood pressure (BP) control in diabetic patients, with reference to a study published in the 2010 issue of the "New England of Journal of Medicine."

  • 2 LITTLE? 2 nutrients to get more of. LIEBMAN, BONNIE // Nutrition Action Health Letter;Sep2015, Vol. 42 Issue 7, p9 

    The article discusses how one can get potassium and magnesium from food, with blood pressure and risk of stroke lowered when one gets enough potassium and risk of type two diabetes lessened when one gets enough magnesium. Topics discussed include higher potassium intake possibly addressing...

  • New Updates in Diabetes. Twedell, Diane // Journal of Continuing Education in Nursing;Mar/Apr2004, Vol. 35 Issue 2, p54 

    Provides new updates in diabetes in the U.S. Introduction of insulin as therapy for diabetes; Advantages of long-acting analogs; Benefits of pump therapy..

  • Insulin Lispro: A Pharmacoeconomic Review of its Use in Diabetes Mellitus. Dunn, C.J.; Plosker, G.L. // PharmacoEconomics;2002, Vol. 20 Issue 14, p989 

    Insulin lispro is a recombinant insulin analogue with transposed amino acids (proline and lysine) at positions 28 and 29 near the C-terminus of the B-chain. The most prominent practical advantage of insulin lispro over human soluble insulin lies in its very rapid onset of action. This property...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics